Mineralys Therapeutics, Inc. Common Stock
Here’s whether Mineralys Therapeutics, Inc. Common Stock (MLYS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); RSI 58 — healthy momentum range; strong 1-year return of +95.6%. Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-0.86% over 10 days); 3-month momentum negative (-5.2%). Currently 38.6% off its 52-week high. Score: -1/7.
MLYS is trading below its 200-day MA ($30.99) — a key warning sign the longer-term trend is under pressure. An RSI of 58.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +95.6% compares to +27.9% for SPY (beat the market by 67.7%). The current 38.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.